



Synthesis And Anti-Tubercular Evaluation of Certain Pyrrole Oxadiazole Derivatives

Prashanth K U*¹, Chethana, Omkar swamy Maradimath², S D Joshi², C S Hallikeri² and Sachin Wali²

¹Dept. of Pharmaceutical chemistry, ²Dept. of Pharmacology, ²Dept. of Pharmaceutics, SET's college of pharmacy, Dharwad.

Received: 10 Oct 2022 / Accepted: 8 Nov 2022/ Published online: 01 Jan 2023

*Corresponding Author Email: prashanthajaramara7@gmail.com

Abstract

The various novel nitrogen containing heterocyclic compounds were synthesized and are screened for antibacterial and antitubercular activities, purity of newly synthesized compounds confirmed by using TLC and structures for the same compounds were confirmed by using IR, NMR, ¹³C and Mass spectrum. Pyrrole ring was constructed by reacting it with 2,5-dimethoxytetrahydrofuran in presence of glacial acetic acid to obtain ethyl 4-pyrrol-1-ylbenzoate (**2**) in good yield. Conversion of ethyl 4-pyrrol-1-ylbenzoate (**2**) into 4-pyrrol-1-ylbenzoic acid hydrazide (**3**), which was achieved by refluxing ethyl 4-pyrrol-1-ylbenzoate (**2**) with hydrazine hydrate in refluxing ethanol. Then this 4-pyrrol-1-ylbenzoic acid hydrazide (**3**) treated with appropriate benzaldehyde to yield compound substituted 2-(4-(1H-pyrrol-1-yl) phenyl)-5-phenyl-1,3,4-oxadiazole **04(a-f)**. Structures of newly synthesised compounds were confirmed on the basis of physico-chemical and spectral data (IR, ¹H & ¹³C-NMR, Mass spectra). All the synthesised compounds were screened for anti-tubercular activity using Microplate Almar Blue Assay (MABA) method. Compounds showed anti-tubercular activity at MIC values between 50 to 3.12 µg/ml when compared with standard drugs Pyrazinamide (3.125 µg/ml) and Streptomycin (6.25 µg/ml). Newly synthesised compounds were also screened for antibacterial activity using broth micro dilution assay method. Compounds showed antibacterial activity at MIC values between 25 to 0.8 µg/ml when compared with standard drugs Ciprofloxacin and Norfloxacin.

Keywords

- pyrrole oxadiazole, anti-tubercular, anti-bacterial, dimethyl sulfoxide.

INTRODUCTION:

Antimicrobial resistance results in increased morbidity and mortality from treatment failures and increased health care costs. It is estimated that USD 30 billion is spent on the cumulative effects of antimicrobial resistance each year including multiple drug regimens, extra hospital days, additional medical care and lost productivity. And a recent study showed that multidrug-resistance was associated with increasing incidence of invasive pneumococcal diseases in children younger than 5 years of age. It means that antibiotic resistance

directly contributes to increasing incidence of invasive diseases.¹

The main mycobacterial infections in humans are *tuberculosis* and *leprosy* both typically chronic infections; caused respectively by *Mycobacterium tuberculosis* and *Mycobacterium leprae*. Tuberculosis was for centuries a major killer disease, less than 40 years ago, new drugs were developed and put to use and tuberculosis came to be seen as an easily curable infection. This is so, no longer the mycobacterium which causes it has come back to haunt us, the multidrug-resistant strains are now common and

strains with increased virulence have emerged.²⁻³ Tuberculosis is a major threat; killing about 2 million people each year. The World Health Organization estimates that 1 billion people will be newly infected in the period 2000-2020, resulting in 35 million more deaths. TB is currently the leading killer of youths, women, and AIDS patients in the world.⁴

HIV infection is the highest risk factor so far identified which increases the chance of latent infection with tubercle bacilli progressing to active tuberculosis by reducing the protection provided by cell mediated immunity. HIV infected persons have a higher frequency of extra-pulmonary tuberculosis, which is more difficult to diagnose than pulmonary tuberculosis. As the association between tuberculosis and HIV infection becomes more widely known, the diagnosis of tuberculosis will begin to carry an additional social stigma. Tuberculosis is out of control in many parts of the world and it is now the world's leading cause of death from a single agent.⁵⁻⁸

The situation has become more critical because of the presence of some complicating factors like, emergence of multi-drug resistant tuberculosis⁹, HIV co-infection⁶, lack of patient compliance with chemotherapy, and variable efficacy of Bacilli-Calmette Guerin (BCG) vaccine. Multi drug resistant tuberculosis is defined as disease due to *M. tuberculosis* that is resistant to Isoniazid and Rifampicin with or without resistance to other drugs. In the years to come tuberculosis is bound to be an important health problem, particularly in immunocompromised host.

Tuberculosis (TB) has infected man since the birth of civilization and despite the introduction of TB chemotherapy in the 1950s it has made a dramatic resurgence in the past decades and it still remains a leading infectious disease worldwide.¹⁰ The major factors explaining the explosion in numbers of infections with *Mycobacterium Tuberculosis* (MTB) are: (i) the deadly synergy with HIV,¹¹⁻¹² (ii) the development and spread of multidrug-resistant strains of MTB (MDR-TB),¹³⁻¹⁵ resistant to all the first-line drugs, and, (iii) more recently, the emergence of extensively drug resistant MTB strains (XDR-TB),¹⁶⁻¹⁷ also resistant to three or more of the six classes of second-line drugs and untreatable using currently available anti-TB drugs. With this background, there have been no new drugs to treat TB, except fluoroquinolone antibiotics recently introduced,¹⁸ in the last 40 years. This reflects the inherent difficulties in developing and clinical testing new agents as well as the lack of pharmaceutical industry research in the area.¹⁹ The priority is the development of a new agent that will shorten the

duration of chemotherapy from the current 6-8 months to 2 months or less, although new drugs with activity against MDR- and XDR-TB and latent TB are also needed.

The recent rise in tuberculosis cases and especially the increase of drug resistant Mycobacteria indicate an urgent need to develop new anti-tuberculosis drugs.

Although many active anti-TB agents have since been developed, a disturbing co-occurrence with the use of these drugs as single agents has been the development of drug resistance. While the development of this resistance can be forestalled through the use of combination regimens.²⁰

Pyrrrole and its derivatives have shown to possess biological activities such as antibacterial²¹, antitumor²², analgesic²³, antitubercular^{24,25}, anti-inflammatory and anti-allergic.²⁶ Several macromolecular antibiotics were isolated from biological sources and their activities were defined.^{27,28}

1,3,4-Oxadiazole ring is associated with many types of biological properties such as anti-inflammatory²⁹⁻³¹, hypoglycemic³², antifungal and antibacterial³³⁻³⁷ activities. On the other hand, some 5- [isoxazolo [5,4-d] pyrimidinyl oxy methyl] - 2 - substituted phenylamino 1,3,4-oxadiazole and -1,3,4-oxadiazole-2(3H)-thione derivatives³⁷ have been reported as significantly active antimicrobials against *Staphylococcus aureus* and *Candida albicans*.

In continued attempts to identify new potent antimycobacterial compounds, we now want to report the investigations on the use of 4-pyrrol-1-yl benzoic acid hydrazide for the synthesis of new pyrrolyl oxadiazole derivatives and evaluate the newly synthesized compounds for antitubercular activity.

MATERIALS AND METHODS USED:

Chemicals are used in the synthesis of the compounds described were purchased from Sigma Aldrich, Spectrochem Pvt Ltd, and S. D. Fine Chem. Ltd, Avra All the chemicals and solvents are purified either by recrystallization or distillation method.

Instruments:

Melting points of synthesized compounds were determined in SHITAL-Digital programmable melting point apparatus [SSI -22(B)] and sometimes using Thiles Tube are uncorrected; IR spectra were recorded on Bruker- α T spectrophotometer by using KBr pellets. The ¹H NMR and ¹³C NMR was recorded on Bruker AvanceIII NMR400/100 MHz instruments using dimethyl sulfoxide (**DMSO-d₆**) as solvents and TMS as internal standard, chemical shifts are expressed as δ values (ppm) and the splitting of the

NMR spectra are termed as singlet (s), doublet (d), doublet of doublet (dd), triplet (t), quartet (q), multiplet (m). Mass spectra on Water-Q-ToF Premier-HAB213, all the compounds' spectra showed the data in consistent with the projected structure and analytical thin layer chromatography (TLC) was performed by using Silica Gel GF and the movement of the solvent is identified by using ultraviolet lamp.


Chemical synthesis:

aminobenzoate II by passing HCl gas in dry ethanolic solution of compound I. By utilizing amino functionality in II, pyrrole ring was constructed by

reacting it with 2,5-dimethoxytetrahydrofuran in presence of glacial acetic acid to obtain ethyl 4-pyrrol-1-yl-benzoate III in good yield.

Conversion of ester III into 4-pyrrol-1-yl-benzoic acid hydrazide IV was straightforward, which was achieved by refluxing ester III with hydrazine hydrate in refluxing ethanol.


Then this hydrazide IV treated with appropriate acyl chlorides produced the intermediates V(a-g) which on cyclisation with P₂O₅ in dry DMF gave 5-substituted oxadiazole VI(a-g).



Synthesis of ethyl 4-aminobenzoate (II)


Dry absolute ethanol (80 ml) was placed in two necked flask equipped with a double surface reflux condenser and a gas inlet tube. Dry hydrogen chloride gas was passed through the dry ethanol until saturated. 4-Aminobenzoic acid (12g, 0.088 mol) was introduced and the mixture was heated under reflux

for 2 hr. upon cooling, the reaction mixture sets to a solid mass of the hydrochloride of ethyl 4-aminobenzoate. The hot solution was poured into water (300 ml) and sodium carbonate was added carefully to the clear solution until it was neutral to litmus. The product thus separated was filtered and recrystallized from ethanol.


Synthesis of ethyl 4-pyrrol-1-yl Benzoate (III):


2,5-Dimethoxytetrahydrofuran (16g, 0.12 mol) was added to ethyl 4-aminobenzoate (16.5 0.1 mol) in ethanol (100ml) and this mixture was heated at

reflux in presence of catalytic amount of acetic acid (0.05ml) for 3hour. After removal of solvent, product is filtered and recrystallized from ethanol.


Synthesis of 4-Pyrrol-1-yl benzoic acid hydrazide (IV):


Compound IV was synthesized by refluxing a mixture of ethyl 4-pyrrol-1-yl benzoate (3.22 g, 0.015 mol)

reflux for 3 hours with hydrazine hydrate (10 ml) in absolute ethanol (10 ml). The reaction mixture was cooled, and crystalline mass obtained was recrystallized from ethanol to secure yellow crystals.


General procedure for the synthesis of N-(aryl carbonyl)-4-(1H-pyrrol-1-yl) benzo hydrazide derivatives:


A mixture of 10 (1 mmol) and substituted acyl chlorides (1.5 mmol) in 10 mL of dry DMF was refluxed for 7–8 h (monitored by TLC). The reaction

mixture was cooled and slowly quenched onto crushed ice with stirring and neutralized with saturated sodium bicarbonate solution. The solid which separated was filtered, washed with cold ethanol, dried and recrystallized from aqueous DMF to give the products.


General procedure for the synthesis of 2-aryl-5-[4-(1Hpyrrol-1-yl) phenyl]-1,3,4-oxadiazole derivatives (VIa-g)

To a suspension of V(a-g) (0.6g, 0.001) in dry DMF (50 mL), phosphorus pentoxide (2.0 g) was added portion wise with stirring at room temperature and the reaction mixture was refluxed for 4 h. The reaction

mixture was cooled and then filtered. The resulting solid that separated was washed with water, dried and recrystallized from aqueous DMF to give the products.



BIOLOGICAL SCREENING

Evaluation of antitubercular Activity: Micro Plate Almar Blue Assay method

Procedure: -

1. The anti-mycobacterial activity of compounds was assessed against *M.tuberculosis* using micro plate Almar Blue assay (MABA) method.
2. This methodology is non-toxic, uses a thermally stable reagent and shows good correlation with proportional and BACTEC radiometric method.
3. Briefly, 200 μ l of sterile deionized water was added to all outer perimeter wells of sterile 96 wells plate to minimize evaporation of medium in the test wells during incubation.
4. The 96 wells plate received 100 μ l of the Middlebrook 7H9 broth and serial dilution of compounds were made directly on plate.
5. The final drug concentrations tested were 100 to 0.2 μ g/ml.
6. Plates were covered and sealed with parafilm and incubated at 37 °C for five days.
7. After this time, 25 μ l of freshly prepared 1:1 mixture of Almar Blue reagent and 10% tween 80 was added to the plate and incubated for 24 hr.
8. A blue colour in the well was interpreted as no bacterial growth, and pink colour was scored as growth.
9. The MIC was defined as the lowest drug concentration which prevented the colour change from blue to pink.

Evaluation of antibacterial activity:

The Minimum Inhibitory Concentration (MIC) determination of the tested compounds was investigated in side-by-side comparison with ciprofloxacin against Gram-positive (*Staphylococcus aureus*, *Bacillus subtilis*) and Gram-negative bacteria (*Klebsiella pneumoniae*, *Escherichia coli*) by broth micro dilution method.

Materials and methods:

1. Mueller-Hinton agar
2. McFarland turbidity standards
3. Scrupulously clean, acid-washed borosilicate glass tubes
4. Micropipette
5. Nutrient agar

Preparation of media:

Sterilization of media and glassware:

The media used in the present study, Mueller-Hinton agar and nutrient agar were sterilized in conical flasks of suitable capacity by autoclaving at 15lb pressure for about 20 minutes. The test tubes and

pipettes were sterilized in a hot air oven at 160°C for 1 h.

Preparation of solution of test compounds:

Serial dilutions of the test compounds and reference drugs were prepared in Mueller-Hinton agar. Drugs (1mg) were dissolved in chloroform (CHCl₃, 1ml). Further progressive dilutions with melted Mueller-Hinton agar were performed to obtain the required concentrations of 0.2, 0.4, 0.8, 1.6, 3.12, 6.25, 12.5, 25, 50 and 100 μ g/ml.

Preparation of the inoculums:

The organisms were sub-cultured on to nutrient agar and incubated overnight at 35°C. The tubes that contain 2ml of Muller-Hinton agar inoculated with five or more colonies from the agar plate and turbidity was adjusted to match a 1 McFarland standard (10⁵cfu/ml) and incubated at 37° C for 18hrs. The MIC was the lowest concentration of the tested compound that yields no visible growth on the plate. To ensure that the solvent had no effect on the bacterial growth, a control was performed with the test medium supplemented with CHCl₃ at the same dilutions as used in the experiments and CHCl₃ had no effect on the microorganisms in the concentrations studied.

Enzyme inhibition studies:

InhA expression and purification:

The production and purification of InHA-6xHis protein from a protease-deficient strain of *E. coli* (BL21) transformed with pHAT5/*InhA* plasmid were performed as follows. A

1 mL of bacteria was grown in 100 mL of Lysogeny broth (LB) medium containing ampicillin (100 μ g/mL) and 2% glucose at 37°C. After 4 h, the solution was re-diluted in 1 L of the same medium and re-grown at 37°C. After attaining the proper concentration (OD₅₉₅=0.6 - 0.8), the culture was centrifuged at 3300 g factor for 10 min at 4°C and bacteria were suspended in LB medium containing ampicillin (100 μ g/mL). Protein expression was induced for overnight incubation in 1 mM isopropyl- β -D-galactopyranoside (IPTG) at 20°C. Cells were harvested by centrifugation at 6000 g for 30 min at 4°C. Dry pellet was kept at -80°C for several months and purification was done with Ni-NTA Agarose from QIAGEN following the manufacturer's protocol. The purified recombinant protein was applied to PD-10 desalting columns (GE Healthcare, Piscataway, NJ) equilibrated with PIPES 30 mM pH 6.8 and 150 mM NaCl to remove the imidazole. Samples were analyzed using SDS-PAGE and Coomassie blue staining and then stored at 4°C for a short-term storage at -80°C with 20% glycerin for long-term storage.


InhA activity inhibition

Triclosan and NADH were obtained from Sigma-Aldrich. Stock solutions of the selected compounds were prepared in DMSO such that the final concentration of this co-solvent was constant at 5% (v/v) in the final volume of 1 mL for all the kinetic reactions. Kinetic assays were performed using trans-2-dodecenoyl-coenzyme A (DDCoA) and wild type *InhA*s previously described. Briefly, the reactions were performed at 25°C in an aqueous buffer (30 mM

PIPES and 150 mM NaCl pH 6.8) containing 250 μM cofactor (NADH), 50 μM substrate (DDCoA) and the test compound (at 50 μM). Reactions were initiated by adding *InhA* (100 nM final) and NADH oxidation was monitored at the fixed wavelength of 340 nm. Inhibitory activity of each derivative was expressed as % inhibition of *InhA* activity (initial velocity of the reaction) with respect to control reaction without the inhibitor.


RESULTS AND DISCUSSION

Table 1. Physico-chemical data of ethyl 4-aminobenzoate (II)




Compound	R	Yield (%)	Recrystallization solvent	M.P. (°C)	Molecular Formula
II	-	65	Ethanol	89-90	C ₉ H ₁₁ NO ₂

Table 2. Physico-chemical data of ethyl 4-pyrrol-1-yl-benzoate (III):




Compound	R	Yield (%)	Recrystallization solvent	M.P. (°C)	Molecular Formula
III	-	70	Ethanol	74-75	C ₁₃ H ₁₃ NO ₂

Table 3: Physicochemical data of 4-pyrrol-1-yl benzoic acid hydrazide (IV)




Compound	R	Yield (%)	Recrystallization solvent	M.P. (°C)	Molecular Formula
IV	-	75	Ethanol	180-182	C ₁₁ H ₁₁ N ₃ O

Table 3: Physico-chemical data of N'-(arylcabonyl)-4-(1H-pyrrol-1-yl) benzohydrazide derivatives (Va-g)




Comp.	R	Yield (%)	Recrystallization solvent	M.P.(°c)	Rf *	Molecular Formula	Mol. weight
Va	3-Br C ₆ H ₄	66	DMF	244-246	0.735	C ₁₈ H ₁₄ BrN ₃ O ₂	283.03
Vb	4-F C ₆ H ₄	76	DMF	260-262	0.754	C ₁₇ H ₁₄ FN ₃ O ₂	323.23
Vc	3-F C ₆ H ₄	65	DMF	288-290	0.777	C ₁₇ H ₁₄ FN ₃ O ₂	323.23
Vd	2-F C ₆ H ₄	63	DMF	264-266	0.715	C ₁₈ H ₁₄ FN ₃ O ₂	323.23
Ve	2-Cl C ₆ H ₄	68	DMF	278-280	0.759	C ₁₈ H ₁₄ ClN ₃ O ₂	339.78
Vf	3-Cl C ₆ H ₄	79	DMF	277-279	0.712	C ₁₈ H ₁₄ ClN ₃ O ₂	339.78
Vg	4-Cl C ₆ H ₄	74	DMF	251-253	0.723	C ₁₈ H ₁₄ ClN ₃ O ₂	339.78

Silica Gel was used as stationary phase, Chloroform: methanol (9:1) as mobile phase and iodine vapour as visualizing agent

Table 4. Physico-chemical data of 2-aryl-5-[4-(1H-pyrrol-1-yl) phenyl]-1,3,4-oxadiazole derivatives (VIa-g)

VIa-g


Comp.	R	Yield (%)	Recrystallisation solvent	M.P.(°c)	Rf *	Molecular Formula	Mol. weight
VIa	3-Br C ₆ H ₄	64	DMF	246-249	0.881	C ₁₈ H ₁₂ BrN ₃ O	287.33
VIb	4-F C ₆ H ₄	76	DMF	252-254	0.843	C ₁₇ H ₁₂ FN ₃ O	305.31
VIc	3-F C ₆ H ₄	66	DMF	263-265	0.804	C ₁₇ H ₁₂ FN ₃ O	305.31
VI d	2-F C ₆ H ₄	56	DMF	250-252	0.854	C ₁₈ H ₁₂ FN ₃ O	305.31
VIe	2-Cl C ₆ H ₄	55	DMF	248-250	0.818	C ₁₈ H ₁₂ ClN ₃ O	321.76
VI f	3-Cl C ₆ H ₄	69	DMF	233-235	0.846	C ₁₈ H ₁₂ ClN ₃ O	321.76
VIg	4-Cl C ₆ H ₄	70	DMF	251-255	0.803	C ₁₈ H ₁₂ ClN ₃ O	321.76

Silica Gel was used as stationary phase, Chloroform: methanol (9:1) as mobile phase and iodine vapour as visualizing agent.

Table 5. Physico-chemical data of 2-aryl-5-[4-(1H-pyrrol-1-yl) phenyl]-1,3,4-oxadiazole derivatives (VIa-g)

VIa-g

Comp.	R	Yield (%)	Recrystallization solvent	M.P.(°c)	Rf *	Molecular Formula	Mol. weight
VIa	3-Br C ₆ H ₄	64	DMF	246-249	0.881	C ₁₈ H ₁₂ BrN ₃ O	287.33
VIb	4-F C ₆ H ₄	76	DMF	252-254	0.843	C ₁₇ H ₁₂ FN ₃ O	305.31
VIc	3-F C ₆ H ₄	66	DMF	263-265	0.804	C ₁₇ H ₁₂ FN ₃ O	305.31
VI d	2-F C ₆ H ₄	56	DMF	250-252	0.854	C ₁₈ H ₁₂ FN ₃ O	305.31
VIe	2-Cl C ₆ H ₄	55	DMF	248-250	0.818	C ₁₈ H ₁₂ ClN ₃ O	321.76
VI f	3-Cl C ₆ H ₄	69	DMF	233-235	0.846	C ₁₈ H ₁₂ ClN ₃ O	321.76
VIg	4-Cl C ₆ H ₄	70	DMF	251-255	0.803	C ₁₈ H ₁₂ ClN ₃ O	321.76

Silica Gel was used as stationary phase, Chloroform:methanol (9:1) as mobile phase and iodine vapour as visualizing agent.

Table 6. Spectral data of 2-aryl-5-[4-(1H-pyrrol-1-yl) phenyl]-1,3,4-oxadiazole derivatives (VIa-g)

VIa-g

Compound	R	IR spectra KBr cm ⁻¹	¹ H NMR spectra (δ-ppm)	¹³ C NMR Spectra (δ-ppm)	MASS Spectra
VIa	3-BrC ₆ H ₄	KBr: 1644.99 (C=N), 1068.44 (C-O-C), 2918.57 (Ar CH=CH Stre). Spectrum no :01	(DMSO-d₆): 400 MHz: 7.50-8.17 (m, 12H pyrrole, C _{3, c4} , C ₅ -H, bridging phenyl C ₂ , C ₃ , C ₅ , C ₆ -H & Phenyl C ₂ , C ₄ , C ₅ , C ₆ -H). Spectrum no :02	(DMSO-d₆): 500 MHz: 118.45 (pyrrole C ₃ , C ₄), 119.50 (bridging phenyl C ₂ , C ₆), 120.44 (pyrrole C ₂ , C ₅), 121.70(bridging phenyl C ₄), 126.46 (bridging phenyl C ₃ , C ₅), 126.89 (phenyl C ₅), 127.41(phenyl C ₂), 130.02 (phenyl C ₁), 136.69 (phenyl C ₃ , C ₆), 142.04 (bridging phenyl C ₁), -----	

				165.23 (Oxadiazole C ₅), 164.34 (Oxadiazole C ₂). Spectrum no :03		
Vlb	4-F C ₆ H ₄	KBr: 1604.81 (C=N), 1101.05 (C-O-C), 2924.34 (Ar CH=CH Stre). Spectrum no :04	(DMSO-d₆): 400 MHz 7.36-8.08 (m, 12H pyrrole C ₂ , C ₃ , C ₄ , C ₅ -H, bridging phenyl C ₂ , C ₃ , C ₅ , C ₆ -H & Phenyl C ₂ , C ₃ , C ₅ , C ₆ -H). Spectrum no :05	-----		(DMSO-d₆): Found= 306.22 [M ⁺¹] Calcd= 305.31 SPECTRU NO: 13
Vlc	3- F C ₆ H ₄	KBr: 1647.04 (C=N), 1071.28 (C-O-C), 2923 (Ar CH=CH Stre). Spectrum no :07	(DMSO-d₆): 400 MHz 6.33 (t, 2H pyrrole C ₃ , C ₄ -H), 7.53(t, 2H Pyrrole C ₂ , C ₅ -H) & 7.60-8.03(m, 8H, bridging phenyl C ₂ , C ₃ , C ₅ , C ₆ -H & Phenyl C ₂ , C ₄ , C ₅ , C ₆ -H). Spectrum no :08	-----		-----
Vld	2- F C ₆ H ₄	KBr: 1637.46 (C=N), 2922.5 (Ar CH=CH Stre). Spectrum no :09	(DMSO-d₆): 400 MHz 6.33-8.12 (m, 12H pyrrole C ₂ , C ₃ , C ₄ , C ₅ -H, bridging phenyl C ₂ , C ₃ , C ₅ , C ₆ -H & Phenyl C ₃ , C ₄ , C ₅ , C ₆ -H). Spectrum no :10	-----		-----
Vle	2- ClC ₆ H ₄	KBr: 1642.52 (C=N), 2922.55 (ArCH=CHStre), 1182.89 (C-O-C). Spectrum no :11	-----	-----		-----
Vlf	3- ClC ₆ H ₄	KBr: 2846.91 (Ar CH=CH Stre), 1686 (C=O), 1094 (C-O-C). Spectrum no :12	-----	-----		-----
Vlg	4- ClC ₆ H ₄	KBr: 2922.41 (Ar CH=CHstre), 1645.20 (C=O). Spectrum no :13	-----	-----		-----

Table no: 7 LIPINSKI RULE OF 5

Compound	Mol. wt	Hydrogen bond donor	Hydrogen bond acceptor	Log p	Lipinskis violations
Vla	365	0	3	4.95	0
Vlb	305	0	3	4.33	0
Vlc	305	0	3	4.33	0
Vld	305	0	3	4.33	0
Vle	321	0	3	4.84	0
Vlf	321	0	3	4.84	0
Vlg	321	0	3	4.84	0

Physicochemical properties of the all the compounds shows the 0 (Zero) violations of Lipinski's Rule of Five.

Biological Evaluation

Antitubercular activity:

All the newly synthesized compounds were screened for the antitubercular activity by Alamar Blue Dye using Microplate Alamar Blue Assay (MABA) method.

Pyrazinamide and Streptomycin were used as standard drugs and activity of all the newly synthesized compounds was measured against them. The MIC was measured.

Table 8: Reveals the antitubercular activity (MIC) of 2-aryl-5-[4-(1H-pyrrol-1-yl) phenyl]-1,3,4-oxadiazole derivatives (Vla-g)

Table 8: Antitubercular screening-Alamar Blue Dye using Microplate Alamar Blue Assay (MABA) method (MIC µg/mL) and enzyme inhibition assay:

Compounds	R	<i>M. tuberculosis</i> H ₃₇ Rv MIC values (µg/mL)	% Inhibition of InhA at 50 µM
Vla	3-Br C ₆ H ₄	3.25	Compounds will be sent to InhA inhibition assay
Vlb	4-F C ₆ H ₄	1.6	
Vlc	3- F C ₆ H ₄	1.6	
sVld	2- F C ₆ H ₄	1.6	
Vle	2- Cl C ₆ H ₄	12.5	
Vlf	3- Cl C ₆ H ₄	12.5	
Vlg	4- Cl C ₆ H ₄	12.5	
Pyrazinamide	-----	3.12 µ/ml	
Streptomycin	-----	6.25 µ/ml	
Triclosan	-----	-----	>99

NT – NOT TESTED, NI – NO INHIBITION

 Table 9: *In vitro* evaluation of antibacterial activity (MIC values in µg/mL)

Compounds	Gram Negative	Gram Positive
	<i>E. coli</i> (µg/mL)	<i>S. aureus</i> (µg/mL)
Vlb	25 µg/mL	50 µg/mL
Vlc	50 µg/mL	25 µg/mL
Ciprofloxacin	2 µg/mL	2 µg/mL

SUMMARY AND CONCLUSION

The present work was intended to synthesize and evaluation of certain pyrrolyl oxadiazole derivatives for their antibacterial and antitubercular activities. The detailed review of literature was carried out for the synthesis. Heterocyclic compounds of pyrrole clubbed with oxadiazole were synthesised as described in scheme I.

Pyrrole ring was constructed by reacting it with 2,5-dimethoxytetrahydrofuran in presence of glacial acetic acid to obtain ethyl 4-pyrrol-1-ylbenzoate (**2**)

in good yield. Conversion of ethyl 4-pyrrol-1-ylbenzoate (**2**) into 4-pyrrol-1-yl-benzoic acid hydrazide (**3**), which was achieved by refluxing ethyl 4-pyrrol-1-ylbenzoate (**2**) with hydrazine hydrate in refluxing ethanol. Then this 4-pyrrol-1-yl-benzoic acid hydrazide (**3**) treated with appropriate benzaldehyde to yield compound substituted 2-(4-(1H-pyrrol-1-yl) phenyl)-5-phenyl-1,3,4-oxadiazole (**04(a-f)**).

Structures of these newly synthesised compounds were confirmed on the basis of their physico-

chemical and spectral data such as IR, ¹H-NMR, ¹³C-NMR and Mass spectra.

The compounds synthesised in the present work were screened for antibacterial activity against Gram +ve (*Staphylococcus aureus*, *Bacillus subtilis*) and Gram -ve (*Klebsiella pneumoniae*, *Escherichia coli*) by using microdilution broth method and antitubercular activity against *Mycobacterium tuberculosis* H₃₇Rv by using Microplate Almar Blue Assay (MABA) method.

The investigation of anti-tubercular screening data revealed that all the tested compounds showed significant activity against *M. Tuberculosis* at range of 3.12 to 50 µg/ml. Compound **4c** were showed highly significant activity at 3.12 µg/ml and Compounds **4b** and **4e** showed significant activity at 6.25µg/ml against *M. Tuberculosis*. Results were depicted in **Table No-06**. From the investigation of antibacterial screening data, it is revealed that all tested compounds showed moderate to good microbial inhibition. Compounds showed antibacterial activity at MIC values of 25-0.8 µg/ml. The compounds 4d and 4e shows highly significant activity at MIC value of 1.6 µg/ml against gram positive bacteria such as *B. subtilis*. Compounds 4d and 4f shows highly significant activity at MIC value of 0.8 µg/ml against gram negative bacteria such as *E. Coli*. Compounds 4a, 4d and 4f shows significant activity at MIC value of 1.6 µg/ml against gram negative bacteria such as *K. pneumonia* and *E. Coli*. Results were depicted in **Table No-07**.

Further studies in this area will not only help to explore the structural features for better efficacy of this class of compounds but also will be instrumental in development of newer classes of antitubercular and antibacterial compounds.

BIBLIOGRAPHY

- Song JH. Global Overview of Antimicrobial Resistance: Historical Perspectives Lectures Isaac 2003;14-6.
- Rang HP, Ritter JM, Moore PK, Dale MM. Pharmacology by 5th ed. New York: Churchill Livingstone; 2003. p. 649-53.
- Bloom BR, Small PM. The evolving relation between humans and *Mycobacterium tuberculosis*. N Engl J Med 1998 Cecil DK, Hideharu I. Synthesis of 1,3-thiazine derivatives and their evaluation as Potential antimycobacterial agents. Eur J Pharm Sci 2002; 15:307-10.
- Soumya S. Clinical Presentation and Treatment of HIV-TB. Ind J Tub 2002; 49:11-6.
- Sharma SK, Mohan A. Co-infection of human immunodeficiency virus (HIV) and tuberculosis: Indian perspective. Ind J Tub 2004; 51:5-16.
- Kamini W. Current issues in HIV/TB co-infection. Ind J Tub 2002; 49:21-6.
- Ranjani R, Soumya S, Sulochana S, Asagar VN, Paramesh P, Paramshivan CN. Mycobacteremia in tuberculosis patients with HIV infection Ind J Tub 2003; 50:29-31.
- Rajendra P. Management of multi-drug resistant tuberculosis: practitioner's view point. Ind J Tub 2007; 54:3-11.
- Global tuberculosis control: surveillance, planning, financing. WHO report 2009. World Health Organization (WHO/HTM/TB/2009.411).
- Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009-21.
- Breen RA, Swaden L, Ballinger J, Lipman MC. Tuberculosis and HIV co-infection: a practical therapeutic approach. Drugs 2006; 66:2299-308.
- Espinal MA. Tuberculosis 2003; 83:44-51.
- Ormerod LP. Br Med Bull 2005;73-74:17-24.
- Caminero JA. Int J Tuberc Lung Dis 2006; 10:829-37.
- Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 2006; 55:301-5.
- Dorman SE, Chaisson RE. Nat Med 2007;13:295-8.
- Tomioaka H. Exp. Opin Drug Disc 2008; 3:21-49.
- O'Brien RJ, Nunn PP. Am J Respir Crit Care Med 2001;1635:1055-8.
- WHO report. 1997.
- Demirayak S, Burun K, Kiraz N. Some pyrrole substituted aryl pyridazinone and pyhalazinone derivatives and their antihypertensive activities. Eur J Med Chem. 1989; 39:95.
- Halazy S, Magnus P. Studies on antitumour agents CC-1065:1-Phenylsulphonyl-1,3-butadiene for the synthesis of 3,3'-bipyroles. Tetrahedron Lett. 1984; 25:1421.
- Li B, Zhang, Goadeng X, Xuebao. 1985; 6:917.
- Bijev A. Pyrrole based hydrazones synthesized and evaluated invitro as potential tuberculostatics. 2006; 56:96-103.
- Sbardella G. Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480. Bioorg Med Chem Lett. 2004; 14:1537-1541.
- Brikner C, Leyck S, Christ B, Kesselring K.German.Patent. 1986:3:506
- Jones A R, Bean P G. The chemistry of pyrroles. Academic Press London. 1997.
- Jones A R. pyrroles part 2. The chemistry of heterocyclic compounds. Wiley New York. 1992.
- Mullican MD, Wilson MW, Conner DT, Kostlan CR, Schrier DJ, Dyer RD. Design of 5-(3, 5-di-tert-butyl-4-hydroxyphenyl)-1, 3, 4-thiadiazoles, -1, 3, 4-oxadiazoles, and-1, 2, 4-triazoles as orally active, non-ulcerogenic anti-inflammatory agents. Journal of medicinal chemistry. 1993 Apr;36(8):1090-9.
- Boschelli DH, Connor DT, Bornemeier DA, Dyer RD, Kennedy JA, Kuipers PJ, Okonkwo GC, Schrier DJ, Wright CD. 1, 3, 4-Oxadiazole, 1, 3, 4-thiadiazole, and 1, 2, 4-triazole analogs of the fenamates: in vitro inhibition of cyclooxygenase and 5-lipoxygenase activities. Journal of medicinal chemistry. 1993 Jun;36(13):1802-10.

30. Raman K, Singh HK, Salzman SK, Parmar SS. Substituted thiosemicarbazides and corresponding cyclized 1, 3, 4-oxadiazoles and their anti-inflammatory activity. *Journal of pharmaceutical sciences*. 1993 Feb;82(2):167-9.
31. Sahin G, Palaska E, Kelicen P, Demirdamar R, Altinok G. Synthesis of Some New 1-Acylthiosemicarbazides, 1, 3, 4-Oxadiazoles, 1, 3, 4-Thiadiazoles and 1, 2, 4-Triazole-3-thiones and their Anti-inflammatory Activities. *Arzneimittelforschung*. 2001 Jun;51(06):478-84.
32. Husain MI, KumaraA, Srivastava RC. Synthesis of N-(2-Naphthyloxyacetyl) thiosemicarbazide and 2-arylamino-5-(2-naphthyloxymethyl)-1,3,4-thiadiazoles/oxadiazoles as oral hypoglycemic agents. *Current Sci*. 1986 Jul 20:644-6.
33. Singh H, Yadav LD. Synthesis of Some 5-Aryl-2-heteroaryl/heteroarylamino-1, 3, 4-oxadiazoles as Potential Fungicides. *Agri and Biolog Chem*. 1976 Apr 1;40(4):759-64.
34. Misra HK. Synthesis of Some New Substituted 1, 3, 4 Oxadiazoles as Potential Insecticidal, Antibacterial and Anti acetylcholine Esterase Agents. *Archiv der Pharmazie*. 1983;316(6):487-93.
35. Giri S, Singh H, Yadav LD. Studies in Oxadiazoles Synthesis of Some 2-Mercapto-1, 3, 4-oxadiazoles and Related Compounds as Potential Fungicides. *Agricultural and Biological Chemistry*. 1976 Jan 1;40(1):17-21.
36. Adhikari VA, Badiger VV. Synthesis and Biological Activities of Isoxazolo (5, 4, d) pyrimidinylloxymethyl thiadiazoles, oxadiazoles and triazoles. *Chem Inform*. 1988 Nov 22;19(47)